EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Vacinas de MRNA e resposta imunológica: mecanismos de ação e eficácia imunológica

Júlia dos Santos Azevedo

Revista ft · 12.11.2026 · 30 (164) · 01-07

DOI: 10.69849/2k57xg49 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista ft, online erschienen am 12.11.2026. Verfasst von Júlia dos Santos Azevedo. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Messenger RNA (MRNA)-based vaccines represent an unprecedented technological revolution in the history of immunology and modern biotechnology, becoming firmly established during the global health crisis triggered by the COVID-19 pandemic. Unlike traditional vaccines, which use attenuated or inactivated pathogens, this innovative platform employs synthetic nucleotide sequences encapsulated in lipid nanoparticles to instruct the host cell machinery to synthesize specific antigens endogenously. This study aimed to conduct an in-depth analysis of the molecular and cellular mechanisms of action of mRNA vaccines, as well as to evaluate their overall immunological efficacy, safety profile, and future therapeutic implications. To this end, a descriptive and analytical integrative literature review was conducted, based on a systematic search of internationally recognized scientific databases, including PubMed, SciELO, Web of Science, and Google Scholar, covering publications from 2019 to 2024. The findings synthesized from the literature demonstrate that MRNA formulations trigger a vigorous and coordinated activation of both innate and adaptive immunity. The internalization of lipid nanoparticles by dendritic cells and macrophages activates pattern recognition receptors (PRRs), inducing the secretion of essential inflammatory cytokines and chemokines. Subsequently, antigen presentation via major histocompatibility complex (MHC) molecules stimulates the activation of helper T lymphocytes (CD4⁺) and cytotoxic T lymphocytes (CD8⁺), alongside the maturation of plasma cells that produce high-affinity neutralizing antibodies and the robust generation of long-lived memory T and B lymphocytes. Documented clinical efficacy exceeded 90% against severe symptomatic disease, highlighting the platform's advantages in terms of structural flexibility and rapid adaptability to the continuous emergence of new viral variants. It is concluded that MRNA vaccines extend beyond the scope of COVID-19 prophylaxis, ushering in a new therapeutic era with potential applications in the management of malignant neoplasms, autoimmune diseases, and chronic viral infections.

Zitieren

APA

Azevedo, J. D. S. (2026). Vacinas de MRNA e resposta imunológica: mecanismos de ação e eficácia imunológica. Revista ft, 30(164), 01-07. https://doi.org/10.69849/2k57xg49

Vancouver

Azevedo JDS. Vacinas de MRNA e resposta imunológica: mecanismos de ação e eficácia imunológica. Revista ft. 2026;30(164):01-07. doi:10.69849/2k57xg49

BibTeX
@article{Azevedo2026,
  author = {Azevedo, Júlia dos Santos},
  title = {Vacinas de MRNA e resposta imunológica: mecanismos de ação e eficácia imunológica},
  journal = {Revista ft},
  year = {2026},
  volume = {30},
  number = {164},
  pages = {01--07},
  doi = {10.69849/2k57xg49}
}
Kostenlos starten →